0000950170-23-062099 | 10-Q | XBRL Viewer

Inventories

9 Months Ended

Sep. 30, 2023

Note 4 – Inventories

Inventories consisted of the following (in thousands):


	September 30,			December 31,
	2023			2022
Finished goods	$	8,734		$	6,408
Raw materials		5,771			6,494
Work-in-process		4,787			2,567
		19,292			15,469
Less: reserve for excess and obsolete inventory		(368	)		(634	)
	$	18,924		$	14,835

At September 30, 2023 and December 31, 2022, finished goods included $5.2 million and $2.8 million of inventory held on consignment at customer sites, respectively.

Leases - Summary of Lease Balances Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets
Operating leases right-of-use assets	$ 2,793	$ 3,943
Assets Finance	$ 46	$ 206
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net	Property and equipment, net
Total lease assets	$ 2,839	$ 4,149
Current liabilities:
Liabilities Current Operating	$ 1,934	$ 1,818
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Lease liabilities	Lease liabilities
Liabilities Current Finance	$ 42	$ 152
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Lease liabilities	Lease liabilities
Noncurrent
Liabilities Noncurrent Operating	$ 1,354	$ 2,813
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term lease liabilities	Long-term lease liabilities
Liabilities Noncurrent Finance	$ 0	$ 43
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term lease liabilities	Long-term lease liabilities
Total lease liabilities	$ 3,330	$ 4,826

Convertible Preferred Stock and Stockholders' Deficit - Summary of Common Stock Reserved for Future Issuance (Details) - shares	Sep. 30, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Conversion of preferred stock	8,656,046	11,816,582
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Conversion of preferred stock	650,682	492,862

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3

+ Details

Term Loan	9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]
Term Loan	Note 6 – Term Loans Refinancing and Payoff of Oxford Debt On October 29, 2020, the Company and Oxford Finance LLC (“Oxford”), as collateral agent, and certain lenders (“Lenders”) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the “May 2022 LSA”), pursuant to which the Lenders provided to the Company certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the “May 2022 Term Loan”). The May 2022 LSA increased the loan and security agreement to $60.0 million, of which $40.0 million was fully drawn upon as of May 3, 2022 from the original term loan. On June 30, 2023, the Company entered into a new Loan and Security Agreement (the “June 2023 LSA”) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $20.0 million in aggregate Term A Loans (the “Term A Loans”). On that same date, the Company prepaid the May 2022 Term Loan in full which included outstanding accrued interest of approximately $0.1 million, and approximately $1.0 million in final payment and other fees using a combination of cash, primarily comprised of $19.4 million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $20.0 million in Term A Loans and $1.7 million in cash reserves. On August 4, 2023, the Company repaid its outstanding June 2023 LSA of $20.0 million early which included outstanding accrued interest of approximately $0.2 million, and approximately $1.0 million in final payment and other fees using $11.9 million of cash, net, raised under the ATM Facility and $9.3 million in cash reserves.

Term Loan

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Term Loan

Note 6 – Term Loans

Refinancing and Payoff of Oxford Debt

On October 29, 2020, the Company and Oxford Finance LLC (“Oxford”), as collateral agent, and certain lenders (“Lenders”) entered into that certain Loan and Security Agreement, as amended by that certain Consent and First Amendment to Loan and Security Agreement, dated as of July 6, 2021, and that certain Second Amendment to Loan and Security Agreement, dated as of May 3, 2022 (the “May 2022 LSA”), pursuant to which the Lenders provided to the Company certain loans in accordance with the terms and conditions of the May 2022 LSA (such loans collectively, the “May 2022 Term Loan”). The May 2022 LSA increased the loan and security agreement to $60.0 million, of which $40.0 million was fully drawn upon as of May 3, 2022 from the original term loan.

On June 30, 2023, the Company entered into a new Loan and Security Agreement (the “June 2023 LSA”) with Oxford as collateral agent and the lenders party thereto, pursuant to which the Company borrowed $20.0 million in aggregate Term A Loans (the “Term A Loans”). On that same date, the Company prepaid the May 2022 Term Loan in full which included outstanding accrued interest of approximately $0.1 million, and approximately $1.0 million in final payment and other fees using a combination of cash, primarily comprised of $19.4 million of net cash raised under the ATM Facility during the quarter ended June 30, 2023, $20.0 million in Term A Loans and $1.7 million in cash reserves.

On August 4, 2023, the Company repaid its outstanding June 2023 LSA of $20.0 million early which included outstanding accrued interest of approximately $0.2 million, and approximately $1.0 million in final payment and other fees using $11.9 million of cash, net, raised under the ATM Facility and $9.3 million in cash reserves.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Short-Term Investment

9 Months Ended

Sep. 30, 2023

Short-Term Investments [Abstract]

Short-Term Investment

Note 3 – Short-Term Investments

Short-term investments, principally U.S. Treasury bills, are available-for-sale and consisted of the following (in thousands):


	As of September 30, 2023
	Amortized Cost		Unrealized Loss, Net			Estimated Fair Value
U.S. Treasury securities	$	122,061	$	(38	)	$	122,023


	As of December 31, 2022
	Amortized Cost		Unrealized Loss, Net			Estimated Fair Value
U.S. Treasury securities	$	94,043	$	(75	)	$	93,968

All available-for-sale securities held as of September 30, 2023 and December 31, 2022 had a maturity of less than one year. The Company has classified all marketable securities, regardless of maturity, as short-term investments based upon the Company’s ability and intent to use any and all of those marketable securities to satisfy the Company’s liquidity requirements.

Stock-Based Compensation Expense - Summary of Stock Option Activities (Details) - The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Options, Beginning balance	6,339,558
Number of Options, Granted	1,398,191
Number of Options, Exercised	(586,789)
Number of Options, Forfeited	(112,390)
Number of Options, Expired	(64,330)
Number of Options, Ending balance	6,974,240	6,339,558
Number of Options, Exercisable	4,152,234
Weighted-Average Exercise Price, Beginning balance	$ 11.88
Weighted-Average Exercise Price, Options Granted	15.95
Weighted-Average Exercise Price, Options Exercised	9.13
Weighted-Average Exercise Price, Options Forfeited	13.15
Weighted-Average Exercise Price, Expired	18.39
Weighted-Average Exercise Price, Ending balance	12.85	$ 11.88
Weighted-Average Exercise Price, Exercisable	$ 11.48
Weighted-Average Remaining Contractual Term (Years), Options outstanding	6 years 7 months 28 days	6 years 5 months 23 days
Weighted-Average Remaining Contractual Term (Years), Exercisable	5 years 3 months 10 days

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities:
Net loss	$ (39,431)	$ (51,146)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,027	2,966
Amortization of right-of-use lease assets	132	95
Amortization of debt issuance costs and premium	287	408
Loss on extinguishment of debt	1,769	0
Amortization of discount on short-term investments	(4,545)	(622)
Stock-based compensation	11,321	8,435
Provision for excess and obsolete inventory	13	454
Change in operating assets and liabilities:
Accounts receivable	(4,288)	(4,159)
Inventories	(4,101)	(7,758)
Prepaid and other assets	997	1,613
Accounts payable	1,408	2,331
Accrued expenses and other liabilities	119	2,387
Net cash used in operating activities	(33,292)	(44,996)
Investing Activities:
Purchases of property and equipment	(3,223)	(2,031)
Maturities of short-term investments	205,000	210,000
Purchases of short-term investments	(228,472)	(178,424)
Net cash (used in) provided by investing activities	(26,695)	29,545
Financing Activities:
Proceeds from term loan	20,000	0
Repayment of term loan	(60,000)	0
Proceeds from issuance of common stock from public offering	54,050	0
Proceeds from issuance of common stock in at-the-market offerings	42,433	0
Proceeds from issuance of common stock	5,890	1,189
Payments for employee taxes related to stock compensation	(1,421)	(643)
Principal payments on finance lease liabilities	(119)	(82)
Payments of deferred offering costs	(647)	(295)
Payments of debt issuance costs	(2,224)	(144)
Net cash provided by financing activities	57,962	25
Effect of foreign exchange rate on cash, cash equivalents and restricted cash	(2)	(23)
Net decrease in cash, cash equivalents and restricted cash	(2,026)	(15,449)
Cash, cash equivalents and restricted cash - beginning of period	12,595	25,172
Cash, cash equivalents and restricted cash - end of period	10,569	9,723
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	1,666	1,518
Cash paid for income taxes	12	3
Cash paid for interest on financing leases	8	12
Cash paid for interest on term loan	3,464	3,025
Right-of-use assets obtained in exchange for lease obligations:
Operating lease	8	1,090
Finance lease	0	311
Lease obligations recorded for right-of-use assets:
Operating lease	8	1,090
Finance lease	0	280
Acquisition of property and equipment included in accounts payable and accrued expenses and other current liabilities	211	151
Deferred offering costs included in accounts payable and accrued liabilities	159	350
Reclassification of deferred financing costs	$ 1,300	$ 0

Fair Value Measurements

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Fair Value Measurements

Note 5 – Fair Value Measurements

The table and disclosures for the periods presented below (in thousands) present the Company’s assets and liabilities measured at fair value on a recurring basis and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine such fair value. The Company did not have any assets or liabilities measured at fair value on a recurring basis within Level 3 fair value measurements.


	As of September 30, 2023
	Level I		Level II		Total
Assets:
Money market securities	$	6,223		—		6,223
U.S. Treasury securities		—		122,023		122,023
Total assets at fair value	$	6,223	$	122,023	$	128,246


	As of December 31, 2022
	Level I		Level II		Total
Assets:
Money market securities	$	8,909		—		8,909
U.S. Treasury securities		—		93,968		93,968
Total assets at fair value	$	8,909	$	93,968	$	102,877

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stock-Based Compensation Expense

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Stock-Based Compensation Expense

Note 7 – Stock-Based Compensation Expense

The Company has three equity incentive compensation plans: the 2006 Plan, the 2015 Plan and the 2021 Plan.

2006 Plan

The 2006 Plan was originally adopted by the Board and approved by the Company’s stockholders in 2006. The 2006 Plan was terminated in 2015 in connection with the adoption of the 2015 Plan and as a result no new awards may be issued under the 2006 Plan. However, the 2006 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2006 Plan.

2015 Plan

The 2015 Plan was originally adopted by the Board and approved by the Company’s stockholders in 2015. The 2015 Plan was most recently amended in March 2021. In July 2021, upon completion of the IPO, the 2015 Plan terminated immediately prior to effectiveness of the 2021 Plan with respect to the grant of future awards. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under the 2015 Plan.

2021 Plan

On July 28, 2021, the 2021 Plan was adopted and approved by the Board and stockholders prior to the IPO and became effective on the business day immediately prior to the effective date of the Company’s IPO registration statement. The 2021 Plan provides for the grant of incentive stock options to employees and any subsidiary corporations’ employees, and for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units (“RSUs”), and performance awards to employees, directors, and consultants and subsidiary corporations’ employees and consultants. The number of shares of the Company’s common stock originally available for issuance under the 2021 Plan was equal to 2,420,135 shares of common stock plus any shares subject to awards granted under the 2015 Plan and the 2006 Plan that, after the effectiveness of the 2021 Plan, expire or otherwise terminate without having been exercised in full, are tendered to or withheld by the Company for payment of an exercise price or for tax withholding obligations, or are forfeited to or repurchased by the Company due to failure to vest, with the maximum number of shares to be added to the 2021 Plan from the 2015 Plan and 2006 Plan equal to 4,569,530 shares of common stock.

Evergreen provision

The number of common shares reserved for issuance under the 2021 Plan will be increased automatically on the first day of each fiscal year beginning with the 2022 fiscal year and ending on the ten year anniversary of the date the Board approved the 2021 Plan, by a number equal to the least of: (i) 7,260,406 shares of our common stock; (ii) 4% of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year; or (iii) such lesser number of shares of our common stock as the administrator may determine. The 2021 Plan is administered by the Board. On January 1, 2022, the number of shares available under the 2021 Plan increased by 1,094,670 shares of common stock pursuant to this feature. On January 1, 2023, the number of shares available under the 2021 Plan further increased by 1,130,735 shares of common stock pursuant to this feature. As of September 30, 2023, the number of shares of the Company’s common stock available for future issuance under the 2021 Plan was equal to 416,652 shares of common stock.

2021 ESPP

On July 28, 2021, the Board and stockholders adopted and approved the 2021 ESPP. As of September 30, 2023, the number of shares of the Company’s common stock available for future issuance under the 2021 ESPP was equal to 614,472 shares of common stock.

The 2021 ESPP provides eligible employees of the Company and its subsidiaries with the opportunity to purchase shares of the Company’s common stock at a purchase price equal to 85% of the common stock’s fair market value on the first trading day or last trading day of each purchase period, whichever is lower. The 2021 ESPP provides for two six-month purchase periods every twelve months: May 1 through October 31 and November 1 through April 30. The initial purchase period began on November 1, 2021.

Evergreen provision

The number of common shares reserved for issuance under the 2021 ESPP plan will be increased automatically on the first day of each fiscal year beginning with the 2022 fiscal year, by a number equal to the least of: (i) 1,452,081 shares; (ii) 1% of the outstanding shares of our common stock on the last day of the immediately preceding fiscal year; or (iii) such other amount as the administrator may determine. The 2021 ESPP is administered by the Board. On January 1, 2022, the number of shares available under the 2021 ESPP increased by 273,667 shares of common stock pursuant to this feature. No additional shares were reserved for issuance on January 1, 2023 pursuant to this feature.

Stock-Based Compensation Expense

The purpose of the 2021 Plan and 2021 ESPP is to provide a means by which eligible recipients of stock awards may be given an opportunity to benefit from increases in the value of the common stock in order to retain or procure the services of the employees, members of the Board and consultants and provide them with an incentive to promote the Company’s success and accomplish corporate goals.

Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary; 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years, or (ii) 1/48th of the total number of shares subject to the option vest and

become exercisable each month over four years.

A summary of the stock option activities related to the Equity Plans for the nine months ended September 30, 2023 is presented below:


	Number of Options			Weighted Average Exercise Price		Weighted Avg Remaining Contractual Life (Years)
Options outstanding as of December 31, 2022		6,339,558		$	11.88		6.48
Granted		1,398,191			15.95
Exercised		(586,789	)		9.13
Forfeited		(112,390	)		13.15
Expired		(64,330	)		18.39
Options outstanding as of September 30, 2023		6,974,240			12.85		6.66
Exercisable as of September 30, 2023		4,152,234		$	11.48		5.28

As of September 30, 2023 and December 31, 2022 the intrinsic value of options vested was $68.2 million and $15.9 million, respectively, and of all options outstanding was $105.0 million and $16.4 million, respectively. During the nine months ended September 30, 2023 and 2022, the total cash received from the exercise of stock options was $5.4 million and $0.7 million, respectively. The total fair value less strike price of these options was $8.4 million and $1.6 million, respectively.

A summary of non-vested restricted stock unit activities for the nine months ended September 30, 2023 is as follows:


				Weighted
				Average
	Number of			Grant Date
	Shares			Fair Value

Unvested at December 31, 2022		492,862		$	15.08
Granted		430,926			16.00
Vested		(261,911	)		14.81
Forfeited		(11,195	)		15.17
Unvested at September 30, 2023		650,682		$	15.80

Stock-based compensation expense was classified in the accompanying condensed consolidated statements of operations and comprehensive income (loss) as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Research and development	$	1,035	$	737	$	2,857	$	2,303
Selling, general and administrative		2,731		1,931		7,642		5,451
Cost of goods sold		305		214		822		681
	$	4,071	$	2,882	$	11,321	$	8,435

As of September 30, 2023 and December 31, 2022, there were 2,822,006 and 2,447,687 unvested options, respectively. As of September 30, 2023 and December 31, 2022, total unrecognized expense related to unvested stock options was approximately $24.6 million and $19.1 million, respectively. Both amounts are expected to be recognized over a weighted average period of approximately 2.6 years.

As of September 30, 2023, and December 31, 2022 , total unrecognized expense related to non-vested restricted stock units was approximately $9.6 million and $6.1 million, respectively. The unrecognized compensation cost is expected to be recognized over a weighted average period of 2.5 years and 2.3 years, respectively.

The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:


	Nine Months Ended September 30,
	2023		2022
	Range	Weighted Average	Range	Weighted Average
Expected volatility	64.9% to 67.7%	65.3%	62.4% to 63.8%	62.8%
Risk-free interest rate	3.4% to 4.6%	4.1%	2.0% to 3.0%	2.3%
Expected life (in years)	5.5 to 6.1 years	6.1 years	6.0 to 10.0 years	6.0 years
Expected dividend yield	0.0%	0.0%	0.0%	0.0%
Grant date fair value	$12.91 to $32.45	$16.89	$10.74 to $15.52	$12.63

Common Stock

Each share of common stock is entitled to one vote. Common stock reserved for future issuance under the Equity Plans, 2021 ESPP and the ATM offering consisted of the following:


	September 30, 2023		December 31, 2022
Stock options issued and outstanding under the Equity Plans		6,974,240		6,339,558
Shares available for future issuance under the Equity Plans		416,652		865,122
Restricted stock units issued under the 2021 Plan		650,682		492,862
Shares available for future issuance under 2021 ESPP		614,472		664,976
Shares available for future sale under the ATM offering (1)		—		3,454,064
Total shares of common stock reserved		8,656,046		11,816,582

(1) Based on the closing stock price of $12.67 as reported on the Nasdaq Global Market on December 30, 2022.

ATM Offering

As of the date of this report, a total of 2,617,964 shares of the Company's common stock, for total gross proceeds of $50.0 million (net proceeds of $47.5 million), have been issued and sold pursuant to the ATM offering, of which 428,000 shares of the Company's common stock, for net proceeds of $11.7 million, were sold during the quarter ended September 30, 2023, which was the remaining authorized value of the common stock under the ATM offering in the third quarter of 2023.

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Common stock par value (USD per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	900,000,000	900,000,000
Common stock shares issued	35,847,685	28,268,389
Common stock outstanding (in shares)	35,847,685	28,268,389
Preferred stock par value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred Shares Issued	0	0
Preferred stock, shares outstanding	0	0

Inventories - Schedule of Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Finished goods	$ 8,734	$ 6,408
Raw materials	5,771	6,494
Work-in-process	4,787	2,567
Inventory gross	19,292	15,469
Less: reserve for excess and obsolete inventory	(368)	(634)
Inventory net	$ 18,924	$ 14,835

Term Loan - Additional Information (Details) - USD ($) $ in Thousands				6 Months Ended	9 Months Ended
	Aug. 04, 2023	Jun. 30, 2023	May 03, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Debt Instrument [Line Items]
Proceeds from issuance of common stock					$ 5,890	$ 1,189
ATM Offering [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Proceeds from issuance of common stock	$ 11,900
August Four Two Thousand Twenty Three [Member]
Debt Instrument [Line Items]
Proceeds from Lines of Credit	9,300
Retired Term Loan [Member]
Debt Instrument [Line Items]
Proceeds from Loan Originations				$ 20,000
Proceeds from Lines of Credit				19,400
Proceeds from Lines of Credit		$ 1,700		1,700
May 2022 Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument face amount			$ 60,000
Accrued interest paid		100
Final payment and other fees		1,000
Proceeds from Loan Originations			$ 40,000
New Loan and Security Agreement [Member]
Debt Instrument [Line Items]
Debt instrument face amount		$ 20,000		$ 20,000
Repayments of Debt	20,000
Accrued interest paid	200
Final payment and other fees	$ 1,000

Organization and Basis of Presentation

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Description of Business

RxSight®, Inc. (the “Company”) is a Delaware corporation headquartered in Aliso Viejo, California with one wholly owned subsidiary located in Amsterdam, Netherlands (“RxSight, B.V.”). The wholly owned subsidiary has a registered branch in the United Kingdom and a wholly owned subsidiary located in Germany (“RxSight GmbH”). The Company is engaged in the research and development, manufacture and sale of light adjustable intraocular lenses used in cataract surgery along with capital equipment used with the lenses.

The Company’s products, which include the light adjustable lens (“LAL®”) and a specially designed machine for delivering light to the eye, the Light Delivery Device (“LDD™”), are approved by the United States (“U.S.”) Food and Drug Administration (“FDA”) primarily for sale in the U.S. and have regulatory approval in the U.S., Europe, Canada and Mexico. The Company began marketing its products in 2019. The LAL is a premium intraocular lens (“IOL”) which is partially reimbursable under Medicare. The Company competes with other IOLs in the premium market.

The accompanying unaudited condensed consolidated financial statements include the accounts of RxSight, Inc. and its wholly owned subsidiaries, RxSight, B.V. and RxSight GmbH. All significant inter-company balances and transactions have been eliminated in consolidation.

Basis of Presentation and Principles of Consolidation

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”). Accordingly, the accompanying unaudited condensed consolidated financial statements do not include all of the information and notes required by GAAP for complete financial statements. The unaudited interim financial statements reflect all adjustments which, in the opinion of management, are necessary for a fair statement of the results for the periods presented. All such adjustments are of a normal and recurring nature. The December 31, 2022 balance sheet data was derived from audited financial statements; however, the accompanying notes to the condensed consolidated financial statements do not include all of the annual disclosures required under GAAP and should be read in conjunction with the audited consolidated financial statements included in the Company’s 2022 Annual Report on Form 10-K filed with the SEC on March 6, 2023. The operating results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results that may be expected for any future periods.

Operating Segments

The Company determined its operating segment on the same basis that it uses to evaluate its performance internally. The Company’s chief operating decision-maker (“CODM”), its Chief Executive Officer, reviews its consolidated operating results for the purpose of allocating resources and evaluating financial performance. The Company determined that it operates and manages its business (including its non-U.S. subsidiaries) in one reportable segment: the research and development, manufacture and sale of light adjustable lenses and related capital equipment.

Liquidity

Shelf Registration Statement

On August 8, 2022, the Company filed a $200.0 million shelf registration statement on Form S-3 (“shelf registration statement”) which became effective on August 12, 2022. The shelf registration statement is effective for three years and permits the Company to sell, from time to time, up to $200.0 million in aggregate value of common stock, preferred stock, debt securities, warrants, and/or units. The shelf registration statement is intended to provide the Company with flexibility to access additional capital. At the time of filing the shelf registration statement, the Company also filed a prospectus supplement to sell up to an aggregate value of $50.0 million dollars of common

stock through an “at-the-market” (“ATM”) offering. The Company sold the remaining authorized value of the common stock of $11.7 million under the ATM offering in the third quarter of 2023.

ATM Offering

As of September 30, 2023, through the ATM offering, a total of 2,617,964 shares of the Company's common stock, for total net proceeds of $47.5 million, have been issued and sold, of which 2,142,089 shares of the Company's common stock, for net proceeds of $41.6 million, were sold during the nine months ended September 30, 2023.

Public Offering

On February 7, 2023, the Company entered into an underwriting agreement with BofA Securities, Inc., in which the Company agreed to issue and sell 4,000,000 shares of the Company's common stock in a public offering (“Public Offering”), pursuant to the shelf registration statement. The shares of common stock were sold at a price to the public of $12.50 per share. Under the terms of the underwriting agreement, the Company also granted the underwriters an option exercisable for 30 days from the date of the underwriting agreement to purchase up to an additional 600,000 shares of common stock on the same terms and conditions. The underwriters' option was exercised in full on February 10, 2023 and closed on February 14, 2023. The Company received net proceeds of approximately $53.6 million from the Public Offering, after deducting underwriters' discounts and commissions of $3.5 million and offering expenses of $0.5 million.

As of September 30, 2023 and December 31, 2022 the Company had cash, cash equivalents and short-term investments of $131.9 million and $105.8 million, respectively.

The Company began generating revenue from its principal operations in 2019. The Company has a limited operating history, and the revenue and income potential of the Company’s business and market are unproven. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. For the three months ended September 30, 2023 and 2022, the Company incurred losses from operations of $12.5 million and $16.0 million, respectively. For the nine months ended September 30, 2023 and 2022, the Company incurred losses from operations of $39.2 million and $48.3 million, respectively. Based on the Company’s anticipated sales growth in relation to the anticipated costs associated with, among other things, its continuing research and development activities and the expansion of its sales and marketing activities, the Company expects to continue to incur net operating losses into the foreseeable future. Successful transition to attaining profitable operations is dependent upon gaining market acceptance of the Company’s products and achieving a level of revenues adequate to support the Company’s cost structure.

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company believes that existing cash resources will be sufficient to meet projected operating requirements for at least 12 months from the date of issuance of the accompanying condensed consolidated financial statements, however for the near future, the Company expects to continue to incur operating losses and negative cash flows. The Company plans to continue to fund its losses from operations using its cash, cash equivalents and short-term investments as of September 30, 2023 and meet its future capital funding needs through equity or debt financings, other third-party funding, collaborations, strategic alliances and licensing arrangements or a combination of these. If the Company raises additional funds by issuing equity securities, its stockholders may experience dilution. Any future debt financing into which the Company enters may impose additional covenants that restrict operations, including limitations on its ability to incur liens or additional debt, pay dividends, repurchase common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity raise may contain terms that are not favorable to the Company or its stockholders. If the Company is required to enter into collaborations and other arrangements to address its liquidity needs, it may have to give up certain rights that limit its ability to develop and commercialize product candidates or may have other terms that are not favorable to the Company or its stockholders, which could materially and adversely affect its business and financial prospects. There can be no assurance that the Company will be able to obtain additional financing on acceptable terms, or at all. If the Company is not able to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible and/or suspend or curtail planned programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects.

Summary of Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Basis of Presentation

Operating Segments

Liquidity and Financial Position

Liquidity

Shelf Registration Statement

stock through an “at-the-market” (“ATM”) offering. The Company sold the remaining authorized value of the common stock of $11.7 million under the ATM offering in the third quarter of 2023.

ATM Offering

Public Offering

As of September 30, 2023 and December 31, 2022 the Company had cash, cash equivalents and short-term investments of $131.9 million and $105.8 million, respectively.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make informed estimates, judgments and assumptions that affect the reported amounts in the condensed consolidated financial statements and disclosures in the accompanying notes as of the date of the accompanying condensed consolidated financial statements. On an on-going basis, management evaluates the most critical estimates and assumptions for continued reasonableness. Actual results may differ materially from the estimates used in the preparation of the accompanying condensed consolidated financial statements under different assumptions or conditions.

Significant Accounting Policies

There have been no significant changes to the accounting policies during the nine months ended September 30, 2023, as compared to the significant accounting policies described in Note 2 of the “Notes to Consolidated Financial Statements” in the Company’s audited consolidated financial statements included in its Annual Report on Form 10-K filed with the SEC on March 6, 2023.

Cash Equivalents

Cash equivalents consist of investments in money market accounts. The Company considers all highly liquid investments with original maturities of three months or less at the date of purchase that can be liquidated without prior notice or penalty to be cash equivalents.

Short-term Investments

Short-term investments are classified based on the maturity date of the related securities. Based on the nature of the assets, the Company’s short-term investments, which are government securities, are classified as available-for-sale and are recorded at their estimated fair value as determined by prices for identical or similar securities at the balance sheet date. The Company’s short-term investments consist of Level 2 financial instruments in the fair value hierarchy. Unrealized gains and losses are recorded as a component of Other Comprehensive Loss within Stockholders’ Equity on the condensed consolidated balance sheets. Realized gains and losses are included as other income (expense) in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss. The cost basis for realized gains and losses on available-for-sale securities is determined on a specific identification basis. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such determination at each balance sheet date. The Company periodically reviews its investments for unrealized losses other than credit losses and whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. In determining whether the carrying value is recoverable, management considers the following factors:

•

whether the investment has been in a continuous loss position for over 12 months;

•

the duration to maturity of investments;

•

intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

The Company had $38,000 and $75,000 of net unrealized losses related to short-term investments as of September 30, 2023 and December 31, 2022, respectively.

Concentration of Credit Risk and Other Risks and Uncertainties

Financial instruments which potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, short-term investments and accounts receivable. The Company’s policy is to invest cash in institutional money market funds and marketable securities of the U.S. government to limit the amount of credit exposure. The Company currently maintains a portfolio of cash equivalents and short-term investments in money

market funds and U.S. treasury bills. A portion of the Company's operating cash is held in accounts in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limits; however, the Company has established guidelines regarding diversification of its investments and their maturities, which are designed to maintain principal and maximize liquidity. The Company has not experienced material losses on cash equivalents and short-term investments.

The Company’s products require approval from the FDA and foreign regulatory agencies before commercial sales can commence. There can be no assurance that the Company’s products will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on the Company’s business and may impact business in the future. In addition, after approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the device approval process.

The Company is subject to risks common to companies in the medical device industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of the Company's products, product liability and the need to obtain additional financing.

The Company is subject to the risks related to global lead times, particularly in Europe and Asia, leading to a supply interruption from the Company's suppliers. In addition, the Company is currently experiencing inflation and longer lead times and limited availability in its supply chain for certain components and has continued exposure to price and supply risk related to anticipated purchases of certain commodities, materials and products used in its business.

Accounts Receivable

The Company has a diverse customer base and as of September 30, 2023 and December 31, 2022 the Company did not have any customers who individually accounted for greater than 10% of accounts receivable. The Company maintains an allowance for credit losses resulting from the inability of its customers, including ambulatory surgery centers, to make required payments. After evaluation of the collectability of accounts receivable, the Company did not record any significant allowance for credit losses as of September 30, 2023 or December 31, 2022.

Fair Value of Financial Instruments

The Company uses fair value measurements to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is measured as the price that would be received from the sale of an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques that are consistent with the market, income or cost approach are used to measure fair value. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels:

Level 1—Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.

Level 2—Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability, for substantially the full term of the asset or liability, through correlation with market data. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data.

Level 3—One or more significant inputs that are unobservable and supported by little or no market activity and reflect the use of significant management judgment and assumptions. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques and significant management judgment or estimation. These include the Black-Scholes option-pricing model which uses inputs such as expected volatility, risk-free interest rate and expected term to determine fair market valuation.

Assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurements. The Company reviews the fair value hierarchy classification at each reporting date. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain assets or liabilities within the fair value hierarchy. The Company did not have any transfers of assets and liabilities between the levels of the fair value measurement hierarchy during the years presented.

The Company’s financial instruments consist principally of cash, cash equivalents, short-term investments, accounts receivable, accounts payable, operating lease liabilities and a term loan. Cash, cash equivalents, accounts receivable and accounts payable are carried at their estimated fair value because of the short-term nature of these assets and liabilities. The Company’s short-term investments in government securities are carried at fair value, determined based on publicly available quoted market prices for identical securities at the measurement date. The Company believes the fair values of its operating lease liabilities at September 30, 2023 and December 31, 2022 and amended term loan as of December 31, 2022 approximated their carrying values, based on the borrowing rates that were available for loans with similar terms as of such date.

Inventories

Inventories consist of raw materials, work-in-process and finished goods. Raw materials are comprised of chemicals and parts used in the production of the Company's lenses, cartridges, and LDDs. Finished goods are comprised of lenses, cartridges, accessories and LDDs. Inventories are valued at the lower of cost or net realizable value. Cost is computed using standard cost, which approximates actual cost on a first-in, first-out basis. The carrying value of inventories is reviewed for potential impairment whenever indicators suggest that the cost of inventories exceeds the carrying value and management adjusts the inventories to its net realizable value. The cost of finished goods and work-in-process is comprised of raw materials, direct labor, other direct costs and related production overhead to the extent that these costs do not exceed the net realizable value of the goods produced. The Company periodically reviews inventories for potential impairment, estimated losses from obsolescence, material expirations or unmarketable inventories or excess inventories and writes down the cost of inventories to net realizable value at the time such determinations are made. Net realizable value is determined using the estimated selling price, in the ordinary course of business, less estimated costs to complete and dispose.

Leases

Lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. Operating lease right-of-use assets and liabilities are recognized when the Company takes possession of the leased property (“Commencement Date”) based on the present value of lease payments over the lease term. The Company estimates the incremental borrowing rate based upon the cost of its own debt financing, current market interest rates and quoted offerings or the rate implicit in the lease. Operating lease right-of-use assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The lease terms used to calculate the right-of-use asset and related lease liability include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Rent expense on noncancelable leases containing known future scheduled rent increases is recorded on a straight-line basis over the term of the respective leases beginning on the Commencement Date. The difference between rent expense and rent paid is accounted for as a component of operating lease right-of-use assets on the accompanying condensed consolidated balance sheets. Landlord improvement allowances and other such lease incentives are recorded as property and equipment and as reduction of the right-of-use leased assets and are amortized on a straight-line basis as a reduction to operating lease costs. Leases with an initial term of 12 months or less are expensed as incurred and are not recorded as right-of-use assets on the condensed consolidated balance sheets.

Net Loss per Share

Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average shares of common stock outstanding for the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average shares of common stock and potentially dilutive securities outstanding for the period determined using the treasury-stock and if-converted methods. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive securities outstanding during the period.

The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact under the treasury stock method was anti-dilutive for the periods presented:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan		6,963,498		1,894,845		5,816,203		1,947,260
Restricted stock units issued under the 2021 Equity Incentive Plan		730,419		546,908		696,696		567,203
Stock issuable in offering period under the 2021 Employee Stock Purchase Plan		35,878		50,250		42,020		48,448

Revenue Recognition

The Company’s revenue is generated from the sale of LALs used in cataract surgery along with a specifically designed machine for delivering light to the eye, the LDD, to adjust the lens post-surgery, as needed. Revenue is recognized from sales of products in the U.S. and Europe. Customers are primarily comprised of ambulatory surgery centers, hospitals, and physician private practices.

The Company recognizes revenues when promised goods or services are transferred to customers at a transaction price that reflects the consideration to which the Company expects to be entitled in exchange for those goods and services. Specifically, the Company applies the following five steps to recognize revenue: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies a performance obligation. The Company applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods promised within each customer contract to determine the individual deliverables in its product offerings as separate performance obligations and assesses whether each promised good or service is distinct. The transaction price is determined based on the consideration expected to be received, based either on the stated value in contractual arrangements or the estimated cash to be collected in non-contracted arrangements. The Company recognizes revenue as the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied, considering whether or not this occurs at a point in time or over time. The Company elected to account for shipping costs as fulfillment costs rather than a promised service and excludes from revenue any taxes collected from customers that are remitted to government authorities.

The Company’s LDD contracts contain multiple performance obligations bundled for one transaction price, with all obligations generally satisfied within one year. For these bundled arrangements, the Company accounts for individual products and services as separate performance obligations if they are distinct, that is, if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company’s LDD contracts include a combination of the following performance obligations: (i) LDD capital asset and related components, (ii) training and (iii) device service (initial year). Each of these three performance obligations are considered distinct. The LDD capital asset is distinct because the customer can benefit from it together with other resources that are readily available to the customer. Training on the use of the machine is offered as a distinct activity after installation of the LDD to enhance the customer’s ability to utilize the machine by having an industry professional provide best practices and customize training to the specific needs of the customer. Each LDD comes with a twelve-month manufacturer’s warranty (service-type) that includes preventative maintenance, unscheduled service (labor and parts) and software updates. After the first year, service contracts can be purchased separately on a standalone basis. The Company recognizes revenue as performance obligations are satisfied by transferring control of the product or service to a customer. Specifically, revenue for the LDD capital asset is recognized at a point in time at installation. Revenue for training is also recorded at a point in time, generally 60 days after installation. Revenue

for the device service is recognized ratably over time after installation, generally 12 months. The Company has determined that the transaction price is the invoice price, net of adjustments, if any. The allocation to the separate performance obligations is based upon the relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. The Company estimates the standalone selling price using the market assessment approach considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, type of customer and market conditions. The Company regularly reviews and updates standalone selling prices as necessary.

LALs are generally held at customer sites on consignment. The single performance obligation is satisfied, and revenue from sales is recognized for LALs upon customer notification that the LALs have been implanted in a patient. For the three and nine months ended September 30, 2023 and 2022, credits related to returns and rebates on list prices were not significant.

The Company has adopted the practical expedient permitting the direct expensing of costs incurred to obtain contracts where the amortization of such costs would occur over one year or less, and it applied to substantially all the Company’s contracts. Revenue for service agreements is recognized ratably over the term of each contract.

For the three and nine months ended September 30, 2023 and 2022, revenue from contracts with customers consisted of the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

LDD (including training)	$	7,932	$	5,688	$	22,127	$	15,941
LAL		13,502		6,526		36,308		15,979
Service warranty, service contracts, and accessories		765		401		2,062		997
	$	22,199	$	12,615	$	60,497	$	32,917

As of September 30, 2023 and December 31, 2022, the Company recognized contract liabilities from sales activity on its condensed consolidated balance sheets of $1,678,000 and $1,187,000, respectively, related to the service agreement performance obligation. Revenue for service agreements is recognized ratably over the term of each contract.

The following table represents the contract liabilities from sales activity for the nine months ended September 30, 2023 and 2022, respectively (in thousands):


	Nine Months Ended September 30,
	2023			2022

Balance at beginning of period	$	1,187		$	540
Additions during the period		2,427			1,417
Revenue recognized during the period		(1,936	)		(916	)
Balance at end of period	$	1,678		$	1,041

For the three and nine months ended September 30, 2023 and 2022, the Company did not have any customers who individually accounted for greater than 10% of revenue.

Stock-Based Compensation Expense

The Company has three equity incentive compensation plans: the Calhoun Vision, Inc. 2006 Stock Plan (“2006 Plan”); the Calhoun Vision, Inc. 2015 Equity Incentive Plan (“2015 Plan”); and the 2021 Equity Incentive Plan (“2021 Plan”), which are collectively referred to as the (“Equity Plans”). The Company also has an employee stock purchase plan, the 2021 Employee Stock Purchase Plan (“2021 ESPP”).

The purpose of the 2021 Plan and 2021 ESPP is to provide a means by which eligible participants may be given an opportunity to benefit from increases in the value of the common stock in order to retain or procure the services

of the employees, members of the board of directors of the Company (the “Board”) and consultants and provide them with an incentive to promote the Company’s success and accomplish corporate goals.

Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.

Prior to the Company's shares being traded on the Nasdaq Global Market, the fair value of the Company’s common stock was determined by the Board at the time of each option grant by considering a number of objective and subjective factors. These factors included the valuation of a select group of public peer group companies within the medical device industry that focus on technological advances and development that the Board believed were comparable to the Company’s operations. Operating and financial performance, the lack of liquidity of the common stock and trends in the broader economy and medical device industry also impacted the determination of the fair value of the common stock. In addition, the Company regularly engaged a third-party valuation specialist to assist with estimates related to the valuation of the Company’s common stock. For all grants subsequent to commencement of trading of the Company's shares on the Nasdaq Global Market in July 2021, the fair value of common stock was determined by using the closing price per share of common stock as reported on the Nasdaq Global Market.

In determining the fair value of the stock options granted, the Company uses the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires the use of assumptions about a number of variables, such as the fair market value of the Company’s common stock, expected term, expected volatility, the risk-free interest rate, and dividend yield as discussed below.

Expected term—The Company’s expected term represents the period that the Company’s stock-based awards are expected to be outstanding. The Company used the simplified method (based on the mid-point between the vesting date and the end of the contractual term) to determine the expected term.

Expected volatility—Prior to the completion of the Company’s initial public offering (“IPO”), when the Company was privately held and did not have any trading history for its common stock, the expected volatility was estimated based on the average historical volatilities for comparable publicly traded medical device companies over a period equal to the expected term of the stock option grants. Comparable companies were chosen based on their similar size, stage in the life cycle and area of specialty. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.

Risk-free interest rate—The risk-free interest rate used is based on the published U.S. Department of Treasury interest rates in effect at the time of stock option grant for zero coupon U.S. Treasury notes with maturities approximating each grant’s expected term.

Dividend yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.

Recent Accounting Pronouncements

Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of accounting standards updates (“ASU”). There have been no recent accounting pronouncements, changes in accounting pronouncements or recently adopted accounting guidance during the three months ended September 30, 2023 that are of significance or potential significance to the Company.

Inventories - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventory held on consignment	$ 5.2	$ 2.8

Term Loan - Future Principal Payments Due Under the Term Loan (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Debt Disclosure [Abstract]
Term loan, net	$ 0	$ 40,169

- Definition

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

+ References + Details

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2023	Oct. 31, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Entity Registrant Name	RxSIGHT, INC.
Entity Central Index Key	0001111485
Entity Tax Identification Number	94-3268801
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Securities Act File Number	001-40690
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	100 Columbia
Entity Address, City or Town	Aliso Viejo
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92656
City Area Code	949
Local Phone Number	521-7830
Trading Symbol	RXST
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		35,861,604

Organization and Basis of Presentation - Additional Information (Details) $ / shares in Units, $ in Millions				3 Months Ended		9 Months Ended
	Feb. 07, 2023 USD ($) $ / shares shares	Aug. 12, 2022 USD ($)	Aug. 08, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) Subsidiary Segment shares	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Subsequent Event [Line Items]
Number of wholly owned subsidiaries \| Subsidiary						1
Number of reportable segment \| Segment						1
Cash, cash equivalents, and short-term investments				$ 131.9		$ 131.9		$ 105.8
Losses from operations				12.5	$ 16.0	$ 39.2	$ 48.3
Maximum [Member]
Subsequent Event [Line Items]
Net proceeds from sale of shares		$ 200.0
IPO [Member]
Subsequent Event [Line Items]
Number of shares sold \| shares	4,000,000
Sale of stock, date	Feb. 07, 2023
Common stock par or stated value per share \| $ / shares	$ 12.5
Additional common shares sold \| shares	600,000
Net proceeds from sale of shares	$ 53.6
Common stock sale underwriting discounts and commission deducted	3.5
Common Stock Offering Costs	$ 0.5
Shelf registration statement [Member]
Subsequent Event [Line Items]
Net proceeds from sale of shares			$ 200.0
ATM Offering [Member]
Subsequent Event [Line Items]
Number of shares sold \| shares						2,617,964
Net proceeds from sale of shares						$ 47.5
ATM Offering [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Number of shares sold \| shares						2,142,089
Net proceeds from sale of shares		$ 50.0		$ 11.7		$ 41.6

Stock-Based Compensation Expense - Additional Information (Details) - USD ($) $ in Thousands		3 Months Ended	9 Months Ended		12 Months Ended
	Jul. 28, 2021	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2023	Jan. 01, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares issued		35,847,685	35,847,685		28,268,389
Shares of common stock reserved		8,656,046	8,656,046		11,816,582
Total unrecognized expense related to unvested stock options		$ 9,600	$ 9,600		$ 6,100
Weighted average period for recognition of expenses			2 years 7 months 6 days
Proceeds from issuance of common stock			$ 5,890	$ 1,189
ATM Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued and sold			2,617,964
Common Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Proceeds from issuance of common stock			$ 50,000
Common Stock [Member] \| ATM Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued and sold		428,000	2,617,964
Proceeds from issuance of common stock		$ 11,700
Net proceeds from issuance of common stock			$ 47,500
Maximum [Member] \| ATM Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued and sold			2,142,089
The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic Value of Vested Options		68,200	$ 68,200		15,900
Intrinsic Value of Outstanding Options		$ 105,000	105,000		$ 16,400
Total Cash Received from the Exercise of Stock Options			5,400	700
Total Fair Value Less Strike Price of Stock Options Exercised			$ 8,400	$ 1,600
Number of Options, Unvested		2,822,006	2,822,006		2,447,687
2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock available for issuance	2,420,135
Common stock shares issued	7,260,406
Shares of common stock reserved		416,652	416,652				1,130,735	1,094,670
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum	4.00%
Weighted average period for recognition of expenses			2 years 6 months		2 years 3 months 18 days
2021 Equity Incentive Plan \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved	4,569,530
The 2015 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total unrecognized expense related to unvested stock options		$ 24,600	$ 24,600		$ 19,100
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock shares issued	614,472
Shares of common stock reserved	1,452,081							273,667
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum	1.00%
2021 Employee Stock Purchase Plan \| Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum	85.00%
Share-based Compensation, Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation, Terms of Award						Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary; 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years, or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.
Stock-Based Compensation, Vesting period						4 years
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares of common stock reserved		650,682	650,682		492,862
Number of Options, Unvested		650,682	650,682

Summary of Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Schedule of Dilutive Securities Excluded from Computation of Loss Per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan		6,963,498		1,894,845		5,816,203		1,947,260
Restricted stock units issued under the 2021 Equity Incentive Plan		730,419		546,908		696,696		567,203
Stock issuable in offering period under the 2021 Employee Stock Purchase Plan		35,878		50,250		42,020		48,448

Schedule of Revenue from Contracts with Customers

For the three and nine months ended September 30, 2023 and 2022, revenue from contracts with customers consisted of the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

LDD (including training)	$	7,932	$	5,688	$	22,127	$	15,941
LAL		13,502		6,526		36,308		15,979
Service warranty, service contracts, and accessories		765		401		2,062		997
	$	22,199	$	12,615	$	60,497	$	32,917

Schedule of Deferred Revenue Activity

The following table represents the contract liabilities from sales activity for the nine months ended September 30, 2023 and 2022, respectively (in thousands):


	Nine Months Ended September 30,
	2023			2022

Balance at beginning of period	$	1,187		$	540
Additions during the period		2,427			1,417
Revenue recognized during the period		(1,936	)		(916	)
Balance at end of period	$	1,678		$	1,041

Inventories (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consisted of the following (in thousands):


	September 30,			December 31,
	2023			2022
Finished goods	$	8,734		$	6,408
Raw materials		5,771			6,494
Work-in-process		4,787			2,567
		19,292			15,469
Less: reserve for excess and obsolete inventory		(368	)		(634	)
	$	18,924		$	14,835

Fair Value Measurements - Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Assets:
Total assets at fair value	$ 128,246	$ 102,877
Money market Securities [Member]
Assets:
Total assets at fair value	6,223	8,909
U.S. Treasury Securities [Member]
Assets:
Total assets at fair value	122,023	93,968
Level I [Member]
Assets:
Total assets at fair value	6,223	8,909
Level I [Member] \| Money market Securities [Member]
Assets:
Total assets at fair value	6,223	8,909
Level I [Member] \| U.S. Treasury Securities [Member]
Assets:
Total assets at fair value	0	0
Level II [Member]
Assets:
Total assets at fair value	122,023	93,968
Level II [Member] \| Money market Securities [Member]
Assets:
Total assets at fair value	0	0
Level II [Member] \| U.S. Treasury Securities [Member]
Assets:
Total assets at fair value	$ 122,023	$ 93,968

Summary of Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Income (Loss) Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock Options Issued And Outstanding Under Plans
Earnings Per Share [Line Items]
Anti-dilutive securities	6,963,498	1,894,845	5,816,203	1,947,260
Restricted Stock Units [Member]
Earnings Per Share [Line Items]
Anti-dilutive securities	730,419	546,908	696,696	567,203
Employee Stock Purchase Plan
Earnings Per Share [Line Items]
Anti-dilutive securities	35,878	50,250	42,020	48,448

Summary of Accounting Policies - Schedule of Revenue From Contracts With Customers (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers	$ 22,199	$ 12,615	$ 60,497	$ 32,917
L D D
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers	7,932	5,688	22,127	15,941
LAL
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers	13,502	6,526	36,308	15,979
Service Warranty Service Contracts And Accessories
Disaggregation Of Revenue [Line Items]
Revenue from contracts with customers	$ 765	$ 401	$ 2,062	$ 997

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Commitments and Contingencies

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9 – Commitments and Contingencies

Letter of credit

The Company has a standby letter of credit, expiring September 30, 2024, issued by a financial institution as required security for one operating lease. The aggregate amount of the letter of credit was $0.2 million and $0.3 million as of September 30, 2023 and December 31, 2022, respectively.

Legal Matters

From time-to-time, the Company may be involved in certain legal proceedings or regulatory matters arising in the ordinary course of business, including without limitation, actions with respect to intellectual property, employment, regulatory, product liability and contractual matters. In connection with these proceedings or matters, the Company regularly assesses the probability and amount (or range) of possible issues based on the developments in these proceedings or matters. A liability is recorded in the consolidated financial statements if it is determined that it is probable that a loss has been incurred, and that the amount (or range) of the loss can be reasonably estimated. Because of the uncertainties related to any pending proceedings or matters, the Company is currently unable to predict their ultimate outcome and, with respect to any legal proceeding or regulatory matter where no liability has been accrued, to make a reasonable estimate of the possible loss (or range of loss) that could result from an adverse outcome. At September 30, 2023 and December 31, 2022, there were no legal proceedings, regulatory matters, or other disputes or claims for which a material loss was considered probable or for which the amount (or range) of loss was reasonably estimable. However, regardless of the outcome, legal proceedings, regulatory matters, and other disputes and claims can have an adverse impact on the Company because of legal costs, diversion of management time and resources, and other factors.

Summary of Accounting Policies

9 Months Ended

Sep. 30, 2023

Accounting Policies [Abstract]

Summary of Accounting Policies

Note 2 - Summary of Accounting Policies

Use of Estimates

Significant Accounting Policies

Cash Equivalents

Short-term Investments

•

whether the investment has been in a continuous loss position for over 12 months;

•

the duration to maturity of investments;

•

intention and ability to hold the investment to maturity and if it is not more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis;

•

the credit rating, financial condition and near-term prospects of the issuer; and

•

the type of investments made.

The Company had $38,000 and $75,000 of net unrealized losses related to short-term investments as of September 30, 2023 and December 31, 2022, respectively.

Concentration of Credit Risk and Other Risks and Uncertainties

Accounts Receivable

Fair Value of Financial Instruments

Level 1—Observable inputs such as unadjusted quoted prices in active markets that are accessible at the measurement date for identical unrestricted assets or liabilities.

Inventories

Leases

Net Loss per Share


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Stock options issued and outstanding under the Calhoun Vision, Inc. 2006 Stock Plan, Calhoun Vision, Inc. 2015 Equity Incentive Plan and the 2021 Equity Incentive Plan		6,963,498		1,894,845		5,816,203		1,947,260
Restricted stock units issued under the 2021 Equity Incentive Plan		730,419		546,908		696,696		567,203
Stock issuable in offering period under the 2021 Employee Stock Purchase Plan		35,878		50,250		42,020		48,448

Revenue Recognition

For the three and nine months ended September 30, 2023 and 2022, revenue from contracts with customers consisted of the following (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022

LDD (including training)	$	7,932	$	5,688	$	22,127	$	15,941
LAL		13,502		6,526		36,308		15,979
Service warranty, service contracts, and accessories		765		401		2,062		997
	$	22,199	$	12,615	$	60,497	$	32,917

The following table represents the contract liabilities from sales activity for the nine months ended September 30, 2023 and 2022, respectively (in thousands):


	Nine Months Ended September 30,
	2023			2022

Balance at beginning of period	$	1,187		$	540
Additions during the period		2,427			1,417
Revenue recognized during the period		(1,936	)		(916	)
Balance at end of period	$	1,678		$	1,041

For the three and nine months ended September 30, 2023 and 2022, the Company did not have any customers who individually accounted for greater than 10% of revenue.

Stock-Based Compensation Expense

Stock option awards are granted with an exercise price of no less than 100% of estimated fair market value on the date of grant. Time based awards generally vest over four years as follows, subject to the optionee’s continuing service: (i) one fourth of the total number of shares vest and become exercisable on the one-year anniversary and then 1/48th of the total number of shares subject to the option vest and become exercisable on each monthly anniversary thereafter for the remaining three years; or (ii) 1/48th of the total number of shares subject to the option vest and become exercisable each month over four years.

Dividend yield—The Company has never paid dividends on its common stock and has no plans to pay dividends on its common stock. Therefore, the Company used an expected dividend yield of zero.

Recent Accounting Pronouncements

Commitments and Contingencies - Additional Information (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Legal proceedings, regulatory matters, legal costs	$ 0	$ 0
Letter of Credit [Member]
Loss Contingencies [Line Items]
Aggregate amount of the letter of credit	$ 200,000	$ 300,000

Stock-Based Compensation Expense - Common stock reserved for future issuance (Details) - shares

Sep. 30, 2023

Dec. 31, 2022

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

8,656,046

11,816,582

Future [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

^[1]

3,454,064

Restricted Stock Units

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

650,682

492,862

Stock options issued and outstanding under the 2006, 2015 and 2021 plans

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

6,974,240

6,339,558

Shares Available For Future Issuance Under The 2006 ,2015 And 2021 Plans [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

416,652

865,122

The 2021 ESPP Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Shares of common stock reserved

614,472

664,976

[1]

Based on the closing stock price of $12.67 as reported on the Nasdaq Global Market on December 30, 2022.

ATM Offering

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Stock-Based Compensation Expense - Summary of Non-Vested Restricted Stock Unit Activities (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested at December 31, 2021 \| shares	492,862
Number of Options, Granted \| shares	430,926
Number of shares, vested \| shares	(261,911)
Number of shares, forfeited \| shares	(11,195)
Unvested at June 30, 2023 \| shares	650,682
Weighted Average Grant Date Fair Value, Beginning Balance \| $ / shares	$ 15.08
Weighted Average Grant Date Fair Value, Options Granted \| $ / shares	16
Weighted average fair value, vested \| $ / shares	14.81
Weighted average fair value, forfeited \| $ / shares	15.17
Weighted average fair value, Ending Balance \| $ / shares	$ 15.8

Leases - Schedule of Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee Lease Description [Line Items]
Finance lease cost	$ 2	$ 5	$ 8	$ 12
Cost of Goods Sold
Lessee Lease Description [Line Items]
Operating lease cost	3	4	10	10
Research and Development
Lessee Lease Description [Line Items]
Operating lease cost	20	83	81	242
Finance lease cost	29	30	92	76
Selling, General and Administrative
Lessee Lease Description [Line Items]
Operating lease cost	440	425	1,326	1,257
Finance lease cost	$ 9	$ 9	$ 27	$ 18

Leases - Schedule of Maturities of Lease Liabilites (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Operating Leases
2023 (remainder)	$ 549
2024	1,960
2025	1,044
2026	79
2027	0
2028	0
Total lease payments	3,632
Less: imputed interest	(344)
Total lease liabilities	3,288
Finance Leases
2023 (remainder)	27
2024	16
2025	0
2026	0
2027	0
2028	0
Total lease payments	43
Less: imputed interest	(1)
Total lease liabilities	$ 42

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 9,859	$ 11,834
Short-term investments	122,023	93,968
Accounts receivable	15,244	10,956
Inventories	18,924	14,835
Prepaid and other current assets	1,897	2,962
Total current assets	167,947	134,555
Property and equipment, net	10,262	10,138
Operating leases right-of-use assets	2,793	3,943
Restricted cash	711	761
Other assets	137	767
Total assets	181,850	150,164
Current liabilities:
Accounts payable	4,105	2,595
Accrued expenses and other current liabilities	12,861	12,672
Lease liabilities	1,976	1,970
Total current liabilities	18,942	17,237
Long-term lease liabilities	1,354	2,856
Term loan, net	0	40,169
Other long-term liabilities	75	0
Total liabilities	20,371	60,262
Commitments and contingencies (Note 9)
Stockholders' deficit:
Common stock, $0.001 par value, 900,000,000 shares authorized, 35,168,041 shares issued and outstanding as of September 30, 2023 and 28,268,389 shares issued and outstanding as of December 31, 2022	36	28
Preferred stock, $0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding	0	0
Additional paid-in capital	746,966	636,001
Accumulated other comprehensive loss	(60)	(95)
Accumulated deficit	(585,463)	(546,032)
Total stockholders' deficit	161,479	89,902
Total liabilities and stockholders' equity	$ 181,850	$ 150,164

Stock-Based Compensation Expense - Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Expected volatility, Weighted Average	65.30%	62.80%
Risk-free interest rate, Weighted Average	4.10%	2.30%
Expected life (in years), Weighted Average	6 years 1 month 6 days	6 years
Expected dividend yield, Weighted Average	0.00%	0.00%
Grant date fair value, Weighted Average	$ 16.89	$ 12.63
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, Minimum	67.70%
Expected volatility, Maximum		63.80%
Risk-free interest rate, Minimum	4.60%
Risk-free interest rate, Maximum		3.00%
Expected life (in years)	6 years 1 month 6 days	10 years
Grant date fair value	$ 32.45	$ 15.52
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected volatility, Minimum	64.90%	62.40%
Risk-free interest rate, Minimum	3.40%	2.00%
Expected life (in years)	5 years 6 months	6 years
Grant date fair value	$ 12.91	$ 10.74

Stock-Based Compensation Expense (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Stock Option Activities

nine months ended September 30, 2023 is presented below:


	Number of Options			Weighted Average Exercise Price		Weighted Avg Remaining Contractual Life (Years)
Options outstanding as of December 31, 2022		6,339,558		$	11.88		6.48
Granted		1,398,191			15.95
Exercised		(586,789	)		9.13
Forfeited		(112,390	)		13.15
Expired		(64,330	)		18.39
Options outstanding as of September 30, 2023		6,974,240			12.85		6.66
Exercisable as of September 30, 2023		4,152,234		$	11.48		5.28

Summary of Non-Vested Restricted stock unit Activities

A summary of non-vested restricted stock unit activities for the nine months ended September 30, 2023 is as follows:


				Weighted
				Average
	Number of			Grant Date
	Shares			Fair Value

Unvested at December 31, 2022		492,862		$	15.08
Granted		430,926			16.00
Vested		(261,911	)		14.81
Forfeited		(11,195	)		15.17
Unvested at September 30, 2023		650,682		$	15.80

Schedule of Stock-Based Compensation Expense

Stock-based compensation expense was classified in the accompanying condensed consolidated statements of operations and comprehensive income (loss) as follows (in thousands):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Research and development	$	1,035	$	737	$	2,857	$	2,303
Selling, general and administrative		2,731		1,931		7,642		5,451
Cost of goods sold		305		214		822		681
	$	4,071	$	2,882	$	11,321	$	8,435

Schedule of Range and Weighted-average Assumptions Used in Black-Scholes Option Pricing Model to Determine the Fair Value of Stock Options

The following table presents the range and weighted-average assumptions, used in the Black-Scholes option pricing model to determine the fair value of stock options:


	Nine Months Ended September 30,
	2023		2022
	Range	Weighted Average	Range	Weighted Average
Expected volatility	64.9% to 67.7%	65.3%	62.4% to 63.8%	62.8%
Risk-free interest rate	3.4% to 4.6%	4.1%	2.0% to 3.0%	2.3%
Expected life (in years)	5.5 to 6.1 years	6.1 years	6.0 to 10.0 years	6.0 years
Expected dividend yield	0.0%	0.0%	0.0%	0.0%
Grant date fair value	$12.91 to $32.45	$16.89	$10.74 to $15.52	$12.63

Schedule of Common stock reserved for future issuance

Each share of common stock is entitled to one vote. Common stock reserved for future issuance under the Equity Plans, 2021 ESPP and the ATM offering consisted of the following:


	September 30, 2023		December 31, 2022
Stock options issued and outstanding under the Equity Plans		6,974,240		6,339,558
Shares available for future issuance under the Equity Plans		416,652		865,122
Restricted stock units issued under the 2021 Plan		650,682		492,862
Shares available for future issuance under 2021 ESPP		614,472		664,976
Shares available for future sale under the ATM offering (1)		—		3,454,064
Total shares of common stock reserved		8,656,046		11,816,582

(1) Based on the closing stock price of $12.67 as reported on the Nasdaq Global Market on December 30, 2022.

ATM Offering

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Stockholders' Equity, Beginning Balance, Amount at Dec. 31, 2021	$ 138,242	$ 27	$ 617,511	$ (20)	$ (479,276)
Stockholders' Equity, Beginning Balance, Shares at Dec. 31, 2021		27,366,746
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	308		308
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		145,922
Shares redeemed for employee tax withholdings, Amount	(362)		(362)
Shares redeemed for employee tax withholdings, Shares		(26,983)
Stock-based compensation expense	2,649		2,649
Unrealized loss on short-term investments and cash equivalents, net of tax	(74)			(74)
Foreign currency translation adjustment	(4)			(4)
Net loss	(17,596)				(17,596)
Stockholders' Equity, Ending Balance, Amount at Mar. 31, 2022	123,163	$ 27	620,106	(98)	(496,872)
Stockholders' Equity, Ending Balance, Shares at Mar. 31, 2022		27,485,685
Stockholders' Equity, Beginning Balance, Amount at Dec. 31, 2021	138,242	$ 27	617,511	(20)	(479,276)
Stockholders' Equity, Beginning Balance, Shares at Dec. 31, 2021		27,366,746
Unrealized loss on short-term investments and cash equivalents, net of tax	(95)
Net loss	(51,146)
Stockholders' Equity, Ending Balance, Amount at Sep. 30, 2022	95,959	$ 28	626,491	(138)	(530,422)
Stockholders' Equity, Ending Balance, Shares at Sep. 30, 2022		27,719,132
Stockholders' Equity, Beginning Balance, Amount at Mar. 31, 2022	123,163	$ 27	620,106	(98)	(496,872)
Stockholders' Equity, Beginning Balance, Shares at Mar. 31, 2022		27,485,685
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	277		277
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		99,743
Stock-based compensation expense	2,904		2,904
Shares issued for the employee stock purchase plan, Amount	459		459
Shares issued for the employee stock purchase plan, Shares		46,051
Unrealized loss on short-term investments and cash equivalents, net of tax	(76)			(76)
Foreign currency translation adjustment	(9)			(9)
Net loss	(16,732)				(16,732)
Stockholders' Equity, Ending Balance, Amount at Jun. 30, 2022	109,986	$ 27	623,746	(183)	(513,604)
Stockholders' Equity, Ending Balance, Shares at Jun. 30, 2022		27,631,479
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	145	$ 1	144
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		110,126
Shares redeemed for employee tax withholdings, Amount	(281)		(281)
Shares redeemed for employee tax withholdings, Shares		(22,473)
Stock-based compensation expense	2,882		2,882
Unrealized loss on short-term investments and cash equivalents, net of tax	55			55
Foreign currency translation adjustment	(10)			10
Net loss	(16,818)				(16,818)
Stockholders' Equity, Ending Balance, Amount at Sep. 30, 2022	95,959	$ 28	626,491	(138)	(530,422)
Stockholders' Equity, Ending Balance, Shares at Sep. 30, 2022		27,719,132
Stockholders' Equity, Beginning Balance, Amount at Dec. 31, 2022	$ 89,902	$ 28	636,001	(95)	(546,032)
Stockholders' Equity, Beginning Balance, Shares at Dec. 31, 2022	28,268,389	28,268,389
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	$ 761		761
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		243,598
Shares redeemed for employee tax withholdings, Amount	(337)		(337)
Shares redeemed for employee tax withholdings, Shares		(24,631)
Stock-based compensation expense	3,295		3,295
Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs, Amount	53,600	$ 5	53,595
Issuance of common stock for public offering, net of underwriting discounts, commissions and offering costs, Shares		4,600,000
Issuance of common stock for at-the-market offerings, net of issuance costs, Amount	10,914	$ 1	10,913
Issuance of common stock for at-the-market offerings, net of issuance costs, Shares		879,341
Unrealized loss on short-term investments and cash equivalents, net of tax	84			84
Foreign currency translation adjustment	2			2
Net loss	(13,212)				(13,212)
Stockholders' Equity, Ending Balance, Amount at Mar. 31, 2023	145,009	$ 34	704,228	(9)	(559,244)
Stockholders' Equity, Ending Balance, Shares at Mar. 31, 2023		33,966,697
Stockholders' Equity, Beginning Balance, Amount at Dec. 31, 2022	$ 89,902	$ 28	636,001	(95)	(546,032)
Stockholders' Equity, Beginning Balance, Shares at Dec. 31, 2022	28,268,389	28,268,389
Unrealized loss on short-term investments and cash equivalents, net of tax	$ 38
Net loss	(39,431)
Stockholders' Equity, Ending Balance, Amount at Sep. 30, 2023	$ 161,479	$ 36	746,966	(60)	(585,463)
Stockholders' Equity, Ending Balance, Shares at Sep. 30, 2023	35,847,685	35,847,685
Stockholders' Equity, Beginning Balance, Amount at Mar. 31, 2023	$ 145,009	$ 34	704,228	(9)	(559,244)
Stockholders' Equity, Beginning Balance, Shares at Mar. 31, 2023		33,966,697
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	2,599		2,599
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		316,092
Stock-based compensation expense	3,955		3,955
Shares issued for the employee stock purchase plan, Amount	536		536
Shares issued for the employee stock purchase plan, Shares		50,504
Issuance of common stock for at-the-market offerings, net of issuance costs, Amount	18,957	$ 1	18,956
Issuance of common stock for at-the-market offerings, net of issuance costs, Shares		834,748
Unrealized loss on short-term investments and cash equivalents, net of tax	(65)			(65)
Foreign currency translation adjustment	1			1
Net loss	(13,804)				(13,804)
Stockholders' Equity, Ending Balance, Amount at Jun. 30, 2023	157,188	$ 35	730,274	(73)	(573,048)
Stockholders' Equity, Ending Balance, Shares at Jun. 30, 2023		35,168,041
Shares issued for the exercise of stock options and vesting of restricted stock units, Amount	1,994		1,994
Shares issued for the exercise of stock options and vesting of restricted stock units, Shares		289,010
Shares redeemed for employee tax withholdings, Amount	(1,084)		(1,084)
Shares redeemed for employee tax withholdings, Shares		(37,366)
Stock-based compensation expense	4,071		4,071
Issuance of common stock for at-the-market offerings, net of issuance costs, Amount	11,712	$ 1	11,711
Issuance of common stock for at-the-market offerings, net of issuance costs, Shares		428,000
Unrealized loss on short-term investments and cash equivalents, net of tax	19			(19)
Foreign currency translation adjustment	(6)			(6)
Net loss	(12,415)				(12,415)
Stockholders' Equity, Ending Balance, Amount at Sep. 30, 2023	$ 161,479	$ 36	$ 746,966	$ (60)	$ (585,463)
Stockholders' Equity, Ending Balance, Shares at Sep. 30, 2023	35,847,685	35,847,685

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of assets and liabilities measured at fair value on recurring basis and the fair value hierarchy of the valuation techniques


	As of September 30, 2023
	Level I		Level II		Total
Assets:
Money market securities	$	6,223		—		6,223
U.S. Treasury securities		—		122,023		122,023
Total assets at fair value	$	6,223	$	122,023	$	128,246


	As of December 31, 2022
	Level I		Level II		Total
Assets:
Money market securities	$	8,909		—		8,909
U.S. Treasury securities		—		93,968		93,968
Total assets at fair value	$	8,909	$	93,968	$	102,877

Leases - Summary of Weighted Average Remaining Lease Term and Discount Rate (Details)	Sep. 30, 2023	Dec. 31, 2022
Weigted average remaining lease term (years)
Weighted average remaining lease term - operating leases	1 year 10 months 6 days	2 years 5 months 1 day
Weighted average remaining lease term - finance leases	4 months 24 days	1 year 3 months 14 days
Weighted average discount rate
Weighted average discount rate - operating leases (as a percent)	10.30%	10.30%
Weighted average discount rate - finance leases (as a percent)	9.40%	9.50%

Leases (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Lease Balance Sheet Information

The following table presents the lease balances within the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 (in thousands):


		September 30,		December 31,
Leases	Classification	2023		2022

Assets
Operating	Operating leases right-of-use assets	$	2,793	$	3,943
Finance	Property and equipment, net		46		206
Total lease assets			2,839		4,149
Liabilities
Current
Operating	Lease liabilities		1,934		1,818
Finance	Lease liabilities		42		152
Noncurrent
Operating	Long-term lease liabilities		1,354		2,813
Finance	Long-term lease liabilities		—		43
Total lease liabilities		$	3,330	$	4,826

Schedule of Component of Lease Expense

For the three and nine months ended September 30, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,
Lease Cost	Classification	2023		2022		2023		2022

Operating lease cost	Cost of sales	$	3	$	4	$	10	$	10
	Research and development		20		83		81		242
	Selling, general and administrative		440		425		1,326		1,257
Finance lease cost	Research and development		29		30		92		76
	Selling, general and administrative		9		9		27		18

Finance lease cost	Interest expense		2		5		8		12

Schedule of Maturities of Lease Liabilities

Maturities of the Company’s operating and finance lease liabilities as of September 30, 2023 were as follows (in thousands):


	Operating			Finance
Year Ended December 31,	Leases			Leases
2023 (remainder)	$	549		$	27
2024		1,960			16
2025		1,044			—
2026		79			—
2027		—			—
2028		—			—
Total lease payments		3,632			43
Less: imputed interest		(344	)		(1	)
Total lease liabilities	$	3,288		$	42

Summary of Weighted Average Remaining Lease Term and Discount Rate

The weighted average remaining lease term and weighted average discount rate used to determine lease liabilities related to the Company’s operating and finance leases as of September 30, 2023 and December 31, 2022 were:


	September 30,			December 31,
Lease Term and Discount Rate	2023			2022
Weighted average remaining lease term (years)
Operating leases		1.85			2.42
Finance leases		0.40			1.29
Weighted average discount rate
Operating leases		10.3	%		10.3	%
Finance leases		9.4	%		9.5	%

Short-Term Investment - Additional Information (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Maximum [Member] \| Government Securities [Member]
Short Term Debt [Line Items]
Investment maturity period	1 year	1 year

Short-Term Investment (Tables)

9 Months Ended

Sep. 30, 2023

Short-Term Investments [Abstract]

Schedule of Short-term Investments Available For Sale


	As of September 30, 2023
	Amortized Cost		Unrealized Loss, Net			Estimated Fair Value
U.S. Treasury securities	$	122,061	$	(38	)	$	122,023


	As of December 31, 2022
	Amortized Cost		Unrealized Loss, Net			Estimated Fair Value
U.S. Treasury securities	$	94,043	$	(75	)	$	93,968

Summary of Accounting Policies - Schedule of Deferred Revenue Activity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Deferred Revenue [Abstract]
Balance at beginning of period	$ 1,187	$ 540
Additions during the period	2,427	1,417
Revenue recognized during the period	(1,936)	(916)
Balance at end of period	$ 1,678	$ 1,041

Stockholders' Equity (Additional Information) (Details) - $ / shares	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Common stock, authorized (in shares)	900,000,000			900,000,000
Preferred stock, shares authorized	100,000,000			100,000,000
Preferred stock par value per share	$ 0.001			$ 0.001
Preferred Shares Issued	0			0
Preferred stock, shares outstanding	0			0
Common stock shares issued	35,847,685			28,268,389
Common stock outstanding (in shares)	35,847,685			28,268,389
Common Stock [Member]
Class of Stock [Line Items]
Common stock outstanding (in shares)	35,847,685	35,168,041	33,966,697	28,268,389	27,719,132	27,631,479	27,485,685	27,366,746

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Short-Term Investment - Schedule of Short-term Investment Available For Sale (Details) - US Treasury Securities [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Short Term Debt [Line Items]
Amortized Cost	$ 122,061	$ 94,043
Unrealized Loss, Net	(38)	(75)
Estimated Fair Value	$ 122,023	$ 93,968

Convertible Preferred Stock and Stockholders' Deficit - Summary of Preferred Stock (Details) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Temporary Equity [Line Items]
Par Value	$ 0.001	$ 0.001
Shares Authorized	100,000,000	100,000,000
Preferred Shares Issued	0	0
Shares Outstanding	0	0

Stock-Based Compensation Expense - Common stock reserved for future issuance (Parenthetical) (Details)	Dec. 31, 2022 $ / shares
Share-Based Payment Arrangement [Abstract]
Stock price	$ 12.67

Summary of Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Unrealized gain (Loss) on short term investments			$ 38,000		$ 75,000
Accounts receivable, percentage			10.00%		10.00%
Allowance for doubtful accounts			$ 0		$ 0
Deferred revenue	$ 1,678,000		$ 1,678,000		$ 1,187,000
Revenue Benchmark [Member] \| Customer Concentration Risk [Member] \| No Customer [Member]
Concentration Risk, Percentage	10.00%	10.00%	10.00%	10.00%

Leases - Additional Information (Details)			9 Months Ended
Leases - Additional Information (Details)	Apr. 01, 2023 USD ($)	Apr. 04, 2022 USD ($)	Sep. 30, 2023 USD ($) ft² Item
Lessee Lease Description [Line Items]
Lease expiration date		Mar. 31, 2025
Sublease agreement		34 months
Lease Rent Payable		$ 11,410
Operating Leases, Rent Expense, Sublease Rentals	$ 5,319
California [Member]
Lessee Lease Description [Line Items]
Operating leases,tenant allowance			$ 900,000
Office, Manufacturing and Warehouse Facility [Member] \| California [Member]
Lessee Lease Description [Line Items]
Number of leases \| Item			4
Area of leased space \| ft²			121,000
Office, Manufacturing and Warehouse Facility [Member] \| California [Member] \| Maximum [Member]
Lessee Lease Description [Line Items]
Lease expiration date			Jan. 31, 2026
Office, Manufacturing and Warehouse Facility [Member] \| California [Member] \| Minimum [Member]
Lessee Lease Description [Line Items]
Lease expiration date			Aug. 31, 2024

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Sales	$ 22,199	$ 12,615	$ 60,497	$ 32,917
Cost of sales	8,468	7,259	24,386	19,011
Gross profit	13,731	5,356	36,111	13,906
Operating expenses:
Selling, general and administrative	19,142	14,926	53,634	42,934
Research and development	7,101	6,388	21,710	19,300
Total operating expenses	26,243	21,314	75,344	62,234
Loss from operations	(12,512)	(15,958)	(39,233)	(48,328)
Other income (expense), net:
Interest expense	(230)	(1,299)	(3,304)	(3,495)
Interest and other income	1,746	439	4,913	681
Loss on extinguishment of term loan	(1,407)	0	(1,769)	0
Loss before income taxes	(12,403)	(16,818)	(39,393)	(51,142)
Income tax expense	12	0	38	4
Net loss	(12,415)	(16,818)	(39,431)	(51,146)
Other comprehensive income (loss)
Unrealized gain (loss)on short-term investments	19	55	38	(95)
Foreign currency translation gain (loss)	(6)	(10)	(3)	(23)
Total other comprehensive (loss) income	13	45	35	(118)
Comprehensive loss	$ (12,402)	$ (16,773)	$ (39,396)	$ (51,264)
Net loss per share:
Attributable to common stock, basic	$ (0.35)	$ (0.61)	$ (1.16)	$ (1.86)
Attributable to common stock, diluted	$ (0.35)	$ (0.61)	$ (1.16)	$ (1.86)
Weighted-average shares used in computing net loss per share:
Attributable to common stock, basic	35,662,397	27,665,842	33,947,331	27,551,333
Attributable to common stock, diluted	35,662,397	27,665,842	33,947,331	27,551,333

Stock-Based Compensation Expense - Schedule of Stock-Based Compensation Expense (Details) - The Calhoun Vision, Inc. 2015 Equity Incentive Plan and the Calhoun Vision, Inc. 2006 Stock Plan [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,071	$ 2,882	$ 11,321	$ 8,435
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,035	737	2,857	2,303
Selling, General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	2,731	1,931	7,642	5,451
Cost of Goods Sold
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 305	$ 214	$ 822	$ 681

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Leases

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Leases

Note 8 – Leases

The Company has operating and finance leases for facilities and certain equipment. Leases with an initial term of 12 months or less are not recorded on the condensed consolidated balance sheets. Lease expense for operating leases is recognized on a straight-line basis over the lease term. The Company does not combine lease and non-lease components in the recognition of lease expense.

As of September 30, 2023 the Company held four leases for office, manufacturing and warehouse facilities in Aliso Viejo, California. The four leases are for approximately 121,000 square feet in the aggregate and expire between August 31, 2024 and January 31, 2026. For one of the facilities operating leases, the lessor provided $900,000 in tenant allowances.

On April 4, 2022, the Company entered into a thirty-four-month sublease agreement for a portion of the 5 Columbia Building, in Aliso Viejo, CA. The sublease commencement date was June 13, 2022 and will expire on March 31, 2025. The base rent receivable is $11,410 per month. On January 4, 2023 the Company entered into a second amendment to the sublease agreement adjusting the base rent receivable to $5,319 per month.

The following table presents the lease balances within the Condensed Consolidated Balance Sheets as of September 30, 2023 and December 31, 2022 (in thousands):


		September 30,		December 31,
Leases	Classification	2023		2022

Assets
Operating	Operating leases right-of-use assets	$	2,793	$	3,943
Finance	Property and equipment, net		46		206
Total lease assets			2,839		4,149
Liabilities
Current
Operating	Lease liabilities		1,934		1,818
Finance	Lease liabilities		42		152
Noncurrent
Operating	Long-term lease liabilities		1,354		2,813
Finance	Long-term lease liabilities		—		43
Total lease liabilities		$	3,330	$	4,826

For the three and nine months ended September 30, 2023 and 2022, the components of operating and finance lease expenses were as follows (in thousands):


		Three Months Ended September 30,				Nine Months Ended September 30,
Lease Cost	Classification	2023		2022		2023		2022

Operating lease cost	Cost of sales	$	3	$	4	$	10	$	10
	Research and development		20		83		81		242
	Selling, general and administrative		440		425		1,326		1,257
Finance lease cost	Research and development		29		30		92		76
	Selling, general and administrative		9		9		27		18

Finance lease cost	Interest expense		2		5		8		12

Maturities of the Company’s operating and finance lease liabilities as of September 30, 2023 were as follows (in thousands):


	Operating			Finance
Year Ended December 31,	Leases			Leases
2023 (remainder)	$	549		$	27
2024		1,960			16
2025		1,044			—
2026		79			—
2027		—			—
2028		—			—
Total lease payments		3,632			43
Less: imputed interest		(344	)		(1	)
Total lease liabilities	$	3,288		$	42


	September 30,			December 31,
Lease Term and Discount Rate	2023			2022
Weighted average remaining lease term (years)
Operating leases		1.85			2.42
Finance leases		0.40			1.29
Weighted average discount rate
Operating leases		10.3	%		10.3	%
Finance leases		9.4	%		9.5	%

Common Stock Warrant Liability - Additional Information (Details) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Class Of Warrant Or Right [Line Items]
Common stock par value per share	$ 0.001	$ 0.001

Subsequent Event (Additional Information) (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 5,890	$ 1,189
Common Stock [Member]
Subsequent Event [Line Items]
Proceeds from issuance of common stock		$ 50,000
ATM Offering [Member]
Subsequent Event [Line Items]
Number of shares issued and sold		2,617,964
ATM Offering [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued and sold	428,000	2,617,964
Proceeds from issuance of common stock	$ 11,700
Net proceeds from issuance of common stock		$ 47,500